title: Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?
authors.forename: Cristina
authors.initials: C
authors.lastname: Gervasoni
authors.forename: Agostino
authors.initials: A
authors.lastname: Riva
authors.forename: Caterina
authors.initials: C
authors.lastname: Impagnatiello
authors.forename: Massimo
authors.initials: M
authors.lastname: Galli
authors.forename: Dario
authors.initials: D
authors.lastname: Cattaneo
mesh_terms: D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D060085:Coinfection / Q000188:drug therapy; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000068898:Raltegravir Potassium; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*
chemical_list: D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D012293:Rifampin